Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Biotech Industry Analysis

UpdatedApr 02, 2026
DataAggregated Company Financials
Companies21
  • 7D-3.5%
  • 3M-8.2%
  • 1Y18.1%
  • YTDn/a

Over the last 7 days, the Biotech industry has dropped 3.5%, driven by pullbacks in Genus and Oxford Biomedica of 3.0% and 6.1%, respectively. In the past year, the industry has gained 18%. Looking forward, earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Apr 2026UK£3.0bUK£893.2mUK£3.0m9.2x1022.4x3.4x
Sat, 28 Feb 2026UK£3.5bUK£875.4m-UK£4,543,418.749.3x-763.6x4x
Mon, 26 Jan 2026UK£3.7bUK£876.0m-UK£28,843,346.7810.4x-128.4x4.2x
Wed, 24 Dec 2025UK£3.2bUK£896.7m-UK£29,518,292.7510.3x-108.6x3.6x
Fri, 21 Nov 2025UK£3.2bUK£895.6m-UK£30,364,792.8111x-104.6x3.5x
Sun, 19 Oct 2025UK£3.3bUK£878.7m-UK£44,555,762.2516.2x-75x3.8x
Tue, 16 Sep 2025UK£3.4bUK£857.0m-UK£85,211,004.1816.6x-39.7x3.9x
Thu, 14 Aug 2025UK£3.1bUK£854.4m-UK£103,515,410.2811.8x-29.7x3.6x
Sat, 12 Jul 2025UK£2.7bUK£854.3m-UK£103,522,422.9313.1x-26.2x3.2x
Mon, 09 Jun 2025UK£2.6bUK£857.2m-UK£104,035,511.0013.4x-25.1x3x
Wed, 07 May 2025UK£2.4bUK£879.0m-UK£68,459,571.8113.3x-35.8x2.8x
Fri, 04 Apr 2025UK£2.3bUK£845.3m-UK£276,460,738.4915.8x-8.2x2.7x
Sun, 02 Mar 2025UK£2.4bUK£844.6m-UK£280,029,519.5518.7x-8.7x2.9x
Tue, 28 Jan 2025UK£2.7bUK£842.0m-UK£295,379,201.6483.3x-9.1x3.2x
Thu, 26 Dec 2024UK£2.5bUK£841.8m-UK£294,573,550.0573.7x-8.6x3x
Sat, 23 Nov 2024UK£2.7bUK£841.3m-UK£295,032,089.1283.5x-9.2x3.2x
Mon, 21 Oct 2024UK£3.0bUK£840.2m-UK£295,584,370.7198.5x-10.1x3.6x
Wed, 18 Sep 2024UK£2.8bUK£832.2m-UK£311,152,946.0190x-9.1x3.4x
Fri, 16 Aug 2024UK£2.6bUK£837.2m-UK£251,740,870.4830.6x-10.5x3.2x
Sun, 14 Jul 2024UK£2.7bUK£835.2m-UK£259,688,980.1330.6x-10.6x3.3x
Tue, 11 Jun 2024UK£2.8bUK£835.6m-UK£272,963,388.9329.8x-10.1x3.3x
Thu, 09 May 2024UK£3.0bUK£836.4m-UK£300,084,358.5631.4x-10x3.6x
Sat, 06 Apr 2024UK£3.0bUK£902.4m-UK£200,893,434.9728.7x-15.2x3.4x
Mon, 04 Mar 2024UK£3.0bUK£897.8m-UK£203,905,345.0533x-14.9x3.4x
Wed, 31 Jan 2024UK£6.4bUK£1.3b-UK£245,323,461.0037.8x-26.2x5.1x
Fri, 29 Dec 2023UK£6.4bUK£1.3b-UK£245,096,788.0038.2x-25.9x5x
Sun, 26 Nov 2023UK£6.3bUK£1.3b-UK£245,852,859.0037.1x-25.5x4.9x
Tue, 24 Oct 2023UK£6.5bUK£1.3b-UK£250,836,330.0039.2x-25.8x5.1x
Thu, 21 Sep 2023UK£6.7bUK£1.3b-UK£229,236,837.0023.6x-29.1x5.3x
Sat, 19 Aug 2023UK£6.6bUK£1.3b-UK£207,866,392.0023.6x-31.8x5.3x
Mon, 17 Jul 2023UK£6.8bUK£1.3b-UK£207,414,117.0023.7x-32.8x5.4x
Wed, 14 Jun 2023UK£7.0bUK£1.3b-UK£205,840,859.0023x-33.9x5.5x
Fri, 12 May 2023UK£9.2bUK£1.3b-UK£205,460,971.0024x-44.6x7.3x
Sun, 09 Apr 2023UK£7.2bUK£1.2b-UK£154,069,522.0024.2x-46.6x5.8x
Price to Earnings Ratio

-46.6x


Total Market Cap: UK£7.2bTotal Earnings: -UK£154,069,522.00Total Revenue: UK£1.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Biotech Industry Price to Earnings3Y Average -47.1x202420252026
Current Industry PE
  • Investors are optimistic on the British Biotechnology industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 1kx which is higher than its 3-year average PE of -47.1x.
  • The 3-year average PS ratio of 3.9x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • Total earnings for the Biotechnology industry have gone up over the last three years and the industry is now profitable.
  • Revenues have declined 10% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, profits have been increasing.

Industry Comparison

How does U.K. Biotech compare with similar industries?

GB Market2.42%
Healthcare4.90%
Biotech-3.47%
Biotech-3.47%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GNS GenusUK£25.402.0%
+UK£33.5m		37.6%PE35.8x
BVXP BioventixUK£16.0015.5%
+UK£11.2m		-32.5%PE11.2x
FARN Faron Pharmaceuticals OyUK£0.4810.3%
+UK£5.2m		-77.1%PE-2.3x
SBTX SkinBioTherapeuticsUK£0.0988.3%
+UK£1.9m		-61.0%PS5.4x
BSFA BSF EnterpriseUK£0.021142.9%
+UK£1.6m		41.7%PS51.6x

Latest News

BSFA
UK£0.021
BSF Enterprise
7D
142.9%
1Y
41.7%
PRTC
UK£1.13
PureTech Health
7D
-1.4%
1Y
-18.6%
BVXP
UK£16.00
Bioventix
7D
15.5%
1Y
-32.5%
AVCT
UK£0.64
Avacta Group
7D
-7.3%
1Y
88.1%
PBX
UK£0.08
ProBiotix Health
7D
14.3%
1Y
-8.6%
OXB
UK£5.60
Oxford Biomedica
7D
-2.6%
1Y
106.6%
AREC
UK£0.66
Arecor Therapeutics
7D
-3.6%
1Y
59.0%
4BB
UK£4.84
4basebio
7D
-5.1%
1Y
-59.2%
GNS
UK£25.40
Genus
7D
2.0%
1Y
37.6%

GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside

Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.
SVNS
UK£0.0026
Solvonis Therapeutics
7D
8.3%
1Y
65.1%
SBTX
UK£0.098
SkinBioTherapeutics
7D
8.3%
1Y
-61.0%
FARN
UK£0.48
Faron Pharmaceuticals Oy
7D
10.3%
1Y
-77.1%
GENF
UK£0.019
Genflow Biosciences
7D
5.4%
1Y
82.2%
SCLP
UK£0.11
Scancell Holdings
7D
-4.3%
1Y
38.0%
HEMO
UK£9.50
Hemogenyx Pharmaceuticals
7D
-6.9%
1Y
398.0%
0KF3
US$18.98
Palatin Technologies
7D
-7.2%
1Y
-32.8%